GENMAB A/S -SP ADR (GMAB) Stock Overview
USA - NASDAQ:GMAB - US3723032062 - ADR
GMAB Key Statistics, Chart & Performance
The current stock price of GMAB is 29.89 USD. In the past month the price increased by 2.82%. In the past year, price increased by 29.28%.
GMAB Latest News, Press Relases and Analysis
GMAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About GMAB
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
GENMAB A/S -SP ADR
Carl Jacobsens Vej 30
Valby 1560 DK
CEO: Jan G. J. van de Winkel
Employees: 2682
Phone: 4570202728
GENMAB A/S -SP ADR / GMAB FAQ
What does GENMAB A/S -SP ADR do?
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
What is the stock price of GENMAB A/S -SP ADR today?
The current stock price of GMAB is 29.89 USD. The price increased by 0.07% in the last trading session.
What is the dividend status of GENMAB A/S -SP ADR?
GMAB does not pay a dividend.
What is the ChartMill technical and fundamental rating of GMAB stock?
GMAB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
How is the valuation of GENMAB A/S -SP ADR (GMAB) based on its PE ratio?
The PE ratio for GENMAB A/S -SP ADR (GMAB) is 14.87. This is based on the reported non-GAAP earnings per share of 2.01 and the current share price of 29.89 USD.
What is the market capitalization of GMAB stock?
GENMAB A/S -SP ADR (GMAB) has a market capitalization of 18.40B USD. This makes GMAB a Large Cap stock.
Can you provide the short interest for GMAB stock?
The outstanding short interest for GENMAB A/S -SP ADR (GMAB) is 0.94% of its float.
GMAB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GMAB. When comparing the yearly performance of all stocks, GMAB is one of the better performing stocks in the market, outperforming 85.5% of all stocks.
GMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to GMAB. Both the health and profitability get an excellent rating, making GMAB a very profitable company, without any liquidiy or solvency issues.
GMAB Financial Highlights
Over the last trailing twelve months GMAB reported a non-GAAP Earnings per Share(EPS) of 2.01. The EPS decreased by -69.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.52% | ||
| ROA | 19.6% | ||
| ROE | 23.9% | ||
| Debt/Equity | 0.02 |
GMAB Forecast & Estimates
26 analysts have analysed GMAB and the average price target is 60.61 USD. This implies a price increase of 102.78% is expected in the next year compared to the current price of 29.89.
For the next year, analysts expect an EPS growth of -51.98% and a revenue growth 22.18% for GMAB